Catalent Oral Content
-
Strategies For De-Risking Early-Phase Oral Small Molecule Drug Development
3/7/2022
A team of experts discuss risk-reduction strategies, critical formulation considerations, and careful technology selection to stretch the often limited quantities of API available for early studies.
-
Strategies To Mitigate Common Pitfalls In Early Drug Development
3/4/2022
Two experts discuss the ways companies can address issues with low bioavailability and the benefits of enlisting an experienced drug development partner.
-
Biotech Enables Accelerated Scale-Up Of A Spray-Drying Program
3/4/2022
A virtual biotech, focused on the development and commercialization of a product to treat advanced solid tumors, partnered for the development, clinical trial supply, and scale-up of a spray-drying program.
-
Leveraging An Integrated Network To Accelerate Spray Drying And Tableting Scale-Up
3/4/2022
A biopharmaceutical company sought to develop a commercially-viable tablet formulation for use in phase 2 studies, utilizing spray drying for solubility enhancement.
-
Quality By Design Principles For Analytical Methods
12/18/2019
A QbD approach was used to solve a high-performance liquid chromatography analytical method problem where impurity peaks had shifting retention times, making identification and quantitation problematic.
-
Improving The Quality Of Life For Allergy Patients
12/18/2019
A unique technology enables administration by sublingual dose and offers several unique benefits that differentiate it from other orally disintegrating tablet technologies on the market.
-
Zydis ODT Provides Better Treatments
12/18/2019
A formulation demonstrates higher patient preference and adherence to prescriptions compared to traditional tablets for Selegiline in Parkinson’s disease and other therapeutic areas.
-
Improved Bioavailability In 12 Weeks
2/26/2018
A lead compound showed clinical promise but had limited bioavailability owing to low solubility. Learn about the challenges, including the molecular characterization and limited budget, and the structured 3-step approach.
-
Real World Dosing Solutions For Patients
1/23/2018
Whether you are considering an orally disintegrating tablet to enhance pharmacokinetics through pregastric absorption, to improve patient compliance, or to gain a marketing advantage for a valued brand, Zydis® fast dissolve can help enhance the value of your investment and increase your product’s potential.
-
Oral Delivery Potential For Macromolecules: Parallel Screening Approach
12/13/2017
To assess the potential for oral delivery of Salmon Calcitonin, Catalent conducted a parallel screening with 2 different technologies targeting duodenal and sublingual biological barriers respectively.